Narrow band imaging‐guided diode laser ablation in recurrent low‐grade non‐muscle‐invasive bladder cancer
UroPrecision · 2026-09 · 4 (3) · 171-179
DOI: 10.1002/uro2.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift UroPrecision, online erschienen am 07.05.2026. Verfasst von Ibrahim A. Khalil und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Low‐grade non‐muscle‐invasive bladder cancer (NMIBC) is characterized by high recurrence rates, resulting in repeated interventions and intensive surveillance. Office‐based transurethral laser ablation (TULA) performed under local anesthesia is a minimally invasive alternative to transurethral resection, and narrow band imaging (NBI) may improve tumor visualization and treatment precision. This study aimed to evaluate the efficacy and safety of NBI‐guided office‐based diode laser ablation for recurrent low‐grade NMIBC and to identify factors associated with recurrence.
Methods
A retrospective review of 71 patients with recurrent Ta low‐grade NMIBC was conducted who underwent diode laser ablation in an outpatient clinic. All patients had negative urine cytology prior to treatment. Demographic, clinical, and tumor‐related variables were recorded. Recurrence was defined as histologically confirmed tumor reappearance on follow‐up cystoscopy. Univariable and multivariable logistic regression analyses were performed to identify predictors of recurrence.
Results
Recurrence occurred in 44 patients (62%). Patients with recurrence were younger (median 52.5 vs. 65 years, p < 0.001) and had lower rates of comorbidities (47.7% vs. 74.1%, p = 0.029). A higher proportion of patients with more than three original tumors was observed in the recurrent group (40.9% vs. 11.1%, p = 0.013). On multivariable analysis, younger age (OR = 0.79, 95% CI: 0.67–0.93, p = 0.006), higher number of ablated tumors (OR = 2.5, 95% CI: 1.14–5.85, p = 0.02), and presence of comorbidities (OR = 324.8, 95% CI: 2.99–352.0, p = 0.016) were independently associated with recurrence.
Conclusion
NBI‐guided office‐based diode laser ablation is a safe and effective option for managing recurrent low‐grade NMIBC.
Zitieren
APA
Khalil, I. A., Altayeb, A. B., AlKabbani, M., Younes, N., Badawi, A., Al‐Qudimat, A. R., & AlRumaihi, K. (2026). Narrow band imaging‐guided diode laser ablation in recurrent low‐grade non‐muscle‐invasive bladder cancer. UroPrecision, 4(3), 171-179. https://doi.org/10.1002/uro2.70069
Vancouver
Khalil IA, Altayeb AB, AlKabbani M, Younes N, Badawi A, Al‐Qudimat AR, et al. Narrow band imaging‐guided diode laser ablation in recurrent low‐grade non‐muscle‐invasive bladder cancer. UroPrecision. 2026;4(3):171-179. doi:10.1002/uro2.70069
BibTeX
@article{Khalil2026,
author = {Khalil, Ibrahim A. and Altayeb, Ahmed B. and AlKabbani, Majd and Younes, Nagy and Badawi, Alaeddin and Al‐Qudimat, Ahmad R. and AlRumaihi, Khalid},
title = {Narrow band imaging‐guided diode laser ablation in recurrent low‐grade non‐muscle‐invasive bladder cancer},
journal = {UroPrecision},
year = {2026},
volume = {4},
number = {3},
pages = {171--179},
doi = {10.1002/uro2.70069}
}
EUVIMED